Janssen submits New Drug Application to FDA for selexipag intravenous injection to treat pulmonary arterial hypertension

Application is for use in adults currently prescribed oral selexipag but temporarily unable to take oral therapy, and is supported by phase 3 study (n=20) which showed IV is suitable to maintain continuous dosing for short periods of time when oral administration is not feasible.

Source:

Biospace Inc.